Key result
SIRT1 activation restores mitochondrial membrane potential and significantly reduces ROS in metabolic syndrome cardiomyocytes.
Why the study?
Upstream mechanisms linking metabolic stress to impaired Ca2+ handling and mitochondrial dysfunction in metabolic syndrome cardiomyocytes remain incompletely defined.
Does SIRT1 activation improve calcium homeostasis and mitochondrial function in metabolic syndrome cardiomyocytes?
Does SIRT1 activation improve calcium homeostasis and mitochondrial function in metabolic syndrome cardiomyocytes?
p-value: p=<0.05
SIRT1 activation restores mitochondrial function and calcium homeostasis in metabolic syndrome cardiomyocytes, highlighting sirtuin-dependent pathways as potential therapeutic targets for metabolic cardiomyopathy.
SIRT1 activation merits exploration as a target in metabolic cardiomyopathy; hypothesis-generating in rodent models and leaves open human translation.
Metabolic syndrome (MetS) is a major contributor to cardiovascular disease and is characterized by impaired Ca 2+ handling and mitochondrial dysfunction in cardiomyocytes. However, the upstream mechanisms linking metabolic stress to these alterations remain incompletely defined. Here, we investigated whether sirtuin signalling coordinates intracellular Ca 2+ homeostasis and mitochondrial function in a high‐sucrose diet‐induced mouse model of MetS. Male BALB/c mice were exposed to 32% sucrose for 24 weeks, followed by isolation of ventricular cardiomyocytes. MetS cardiomyocytes exhibited mitochondrial depolarization, increased reactive oxygen species production, elevated basal cytosolic Ca 2+ levels, reduced Ca 2+ transient amplitude and decreased sarcoplasmic reticulum Ca 2+ content. These alterations were associated with reduced phospholamban phosphorylation, increased CaMKII and ryanodine receptor phosphorylation and activation of pro‐apoptotic signalling. Notably, pharmacological inhibition of SIRT1 with EX527 in control cardiomyocytes recapitulated key features of the MetS phenotype, whereas SIRT1 activation with SRT1720 restored mitochondrial membrane potential, reduced reactive oxygen species production, improved Ca 2+ handling, normalized aberrant phosphorylation of Ca 2+ ‐handling proteins and attenuated apoptotic signalling. Collectively, these findings identify SIRT1 as a critical integrator of mitochondrial function and Ca 2+ homeostasis during metabolic stress, highlighting sirtuin‐dependent pathways as promising therapeutic targets in metabolic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Akat et al. (2026) studied Metabolic syndrome (n=15). SIRT1 activation (SRT1720) vs. Untreated MetS cardiomyocytes was evaluated on Mitochondrial membrane potential and ROS production (p=<0.05). SIRT1 activation with SRT1720 restored mitochondrial membrane potential and reduced reactive oxygen species production in metabolic syndrome cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: